Interim Report Third Quarter 2022

July–September 2022, Group

• Net sales amounted to SEK 0 thousand (0)
• Loss before tax amounted to SEK -28,651 thousand (-13,890)
• Earnings per share before dilution amounted to SEK -1.39 (-0.73)
• Cash flow from operating activities amounted to SEK -23,091 thousand (-16,524)
• Cash flow from investing activities amounted to SEK -29,126 thousand (-20,086)

January–September 2022, Group

• Net sales amounted to SEK 0 thousand (0)
• Loss before tax amounted to SEK -76,450 thousand (-44,754)
• Earnings per share before dilution amounted to SEK -3.70 (-2.35)
• Cash flow from operating activities amounted to SEK -75,176 thousand (-41,327)
• Cash flow from investing activities amounted to SEK -105,864 thousand (-72,127)
• Cash and cash equivalents at the end of the period amounted to SEK 89,834 thousand (216,543)

Significant events during the quarter

• In early August, BMS added a further patent regarding crystalline compounds to the ongoing dispute concerning XS004. BMS has previously asserted this patent against other parties in similar cases, so this was not unexpected. Xspray Pharma has not applied for FDA approval for marketing a product that could infringe on the patent in question. Consequently, Xspray Pharma is still convinced of a positive outcome in the legal dispute, and does not expect that this will result in any delays in the case.

Significant events after the end of the reporting period

• In October, a directed share issue was conducted for a number of Swedish institutional investors including the Third Swedish National Pension Fund, Flerie Invest and the Foundation for Baltic and East European Studies. The subscription price was set at SEK 50.00 per share, and the issue raised proceeds of SEK 100 million before transaction costs. The number of shares increased by 2,000,000, from 20,680,408 to 22,680,408.
• In October, the composition of the Nomination Committee for the 2023 Annual General Meeting was announced.
• In early November, Xspray announced that they will attend with two poster presentations for XS004 at the annual American Society of Hematology (ASH) meeting in December 2022.

“To start, I can conclude that the world looks much different with a tough situation on the financial market during the third quarter compared with how the year started. From this perspective I am particularly pleased that, after the end of the quarter, we completed a directed share issue that was fully subscribed and strengthened our shareholder base with a new owner: the Third Swedish National Pension Fund, AP3. The proceeds will be used for initiatives such as market preparation for the upcoming launch on the US market and for strengthening the company’s financials.” – Per Andersson CEO